Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
GXI.DE
HoldSecond WindGerresheimer AG · Healthcare · Germany · $1.1B · Avg Vol: $6M/d
COMPANY DESCRIPTION
Gerresheimer AG manufactures specialty glass and plastic packaging solutions, such as vials, syringes, and drug delivery systems, for the global pharmaceutical industry. Its competitive advantage is protected by strict regulatory validation standards, high switching costs for pharmaceutical clients, and clean-room manufacturing. The company is an essential, highly integrated global partner to major biotech and pharmaceutical firms.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.5B | 1.8B | 2.0B | 2.0B | 2.3B | 11.6% | 2.3B | 2.4B | 2.5B | 3.1% |
| EPS (EUR) | 2.67 | 3.06 | 3.48 | 2.38 | -9.27 | -3.8% | -9.28 | — | — | — |
| Shares | 31.4M | 31.4M | 34.5M | 34.5M | 34.5M | +10.0% | 34.5M | — | — | — |
| Debt | 1.1B | 1.2B | 1.0B | 1.3B | 2.2B | 17.7% | 2.3B | — | — | — |
| Equity | 993.8M | 1.2B | 1.4B | 1.5B | 1.1B | 2.1% | — | — | — | — |
| Op CF | 212.1M | 221.9M | 294.3M | 239.0M | 209.5M | -0.3% | 209.6M | — | — | — |
| Inv CF | -197.0M | -256.2M | -307.4M | -344.2M | -661.8M | — | — | — | — | — |
| Fin CF | 8.0M | 44.2M | 40.3M | 168.3M | 453.0M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of GXI.DE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| GXI.DE | Gerresheimer AG(you) | $1.1B | 50 | Hold |
| FIE.DE | Fielmann Group AG | $3.8B | 72 | Buy |
| AFX.DE | Carl Zeiss Meditec AG | $3.3B | 77 | Buy |
| NNNN | Anbio Biotechnology | $337M | 18 | Strong Sell |
| SRT3.DE | Sartorius Aktiengesellschaft | $20.3B | 54 | Hold |
| EUZ.DE | Eckert & Ziegler SE | $960M | 78 | Buy |
| FYB.DE | Formycon AG | $380M | 38 | Hold |
| IFRX | InflaRx N.V. | $329M | 39 | Hold |
| EVO | Evotec SE | $679M | 22 | Sell |
| RHK.DE | RHÖN-KLINIKUM Aktiengesellschaft | $1.1B | 87 | Strong Buy |
Peer medians: ROE 6.9% · P/E 16.3x · Gross margin 45.7%